Cargando…

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database

Tofacitinib is an oral, small-molecule Janus kinase inhibitor approved in South Korea for the treatment of moderate to severe ulcerative colitis (UC) on May 1, 2019. However, safety data are lacking. We investigated the incidence of serious adverse events (SAEs) in patients with UC using tofacitinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Gi Hyeon, Jung, Sung Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039199/ https://www.ncbi.nlm.nih.gov/pubmed/35470598 http://dx.doi.org/10.3346/jkms.2022.37.e123

Ejemplares similares

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2023)

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
por: Winthrop, Kevin L., et al.
Publicado: (2022)

The role and prospect of tofacitinib in patients with ulcerative colitis
por: Lee, Jun
Publicado: (2023)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
por: Chiorean, Michael, et al.
Publicado: (2023)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
por: Bae, Sung Hun, et al.
Publicado: (2022)

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
por: Schreiber, Stefan, et al.
Publicado: (2023)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Review article: guide to tofacitinib dosing in patients with ulcerative colitis
por: Irving, Peter M., et al.
Publicado: (2022)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
por: Bodryagina, Evgenia, et al.
Publicado: (2022)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
por: Neudorfer, Carolina, et al.
Publicado: (2023)

Adverse Events with the Pfizer-BioNTech COVID-19 Vaccine among Korean Healthcare Workers
por: Im, Jae Hyoung, et al.
Publicado: (2021)

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
por: Long, Millie D, et al.
Publicado: (2022)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
por: Varyani, Fumi, et al.
Publicado: (2019)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
por: Lichtenstein, Gary R., et al.
Publicado: (2023)

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
por: Malakar, Sayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vc1o24hln8pj6lj4i6tcras22d